Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius Stedim Biotech : The underlying trend is to the upside

share with twitter share with LinkedIn share with facebook
share via e-mail
08/12/2019 | 03:12am EDT
long trade
Live
Entry price : 136.7€ | Target : 155€ | Stop-loss : 126€ | Potential : 13.39%
Shares in Sartorius Stedim Biotech show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the € 155.
Chart SARTORIUS STEDIM BIOTECH
Duration : Period :
Sartorius Stedim Biotech Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • The company returns high margins, thereby supporting business profitability.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 111.1 EUR

Weaknesses
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • With an expected P/E ratio at 49.53 and 43.9 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company is not the most generous with respect to shareholders' compensation.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
Ratings chart
Subsector Medical Equipment, Supplies & Distribution - NEC
1st jan.Capitalisation (M$)Investor Rating
SARTORIUS STEDIM BIOTECH53.86%13 541
MEDTRONIC PLC11.86%136 463
BAXTER INTERNATIONAL INC.32.13%43 795
HOYA CORPORATION29.55%29 718
ZIMMER BIOMET HOLDINGS32.10%27 744
TERUMO CORP-45.97%23 173
DEXCOM, INC.36.63%14 456
ALIGN TECHNOLOGY-15.35%13 927
STERIS PLC42.23%12 870
SYSMEX CORP20.99%12 464
SARTORIUS AG (PREFERENCE)58.13%12 093
Autres valeurs du secteur

Jordan Dufee
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2019 1 396 M
EBIT 2019 349 M
Net income 2019 250 M
Debt 2019 46,1 M
Yield 2019 0,49%
P/E ratio 2019 49,5x
P/E ratio 2020 43,8x
EV / Sales2019 8,91x
EV / Sales2020 7,92x
Capitalization 12 389 M
Upcoming event on SARTORIUS STEDIM BIOTECH
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 6
Average target price 134,00  €
Last Close Price 134,40  €
Spread / Highest target 10,1%
Spread / Average Target -0,30%
Spread / Lowest Target -19,6%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Liliane de Lassus Independent Non-Executive Director
Bernard Lemaître Non-Executive Director